After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for Mersana Therapeutics Inc. (MRSN) shows that investor sentiment remained same, with the stock’s consolidated last price remained same to $1.42. The Mersana Therapeutics Inc. has recorded 17,651 volume in the after hours trading session. Most recently, Yahoo Finance reported about the stock as it publicized that Mersana Therapeutics Announces Changes in Leadership.
MRSN belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $1.42 and fluctuated between $1.4800 as its day high and $1.3700 as its day low. The current market capitalization of Mersana Therapeutics Inc. is $178.39M. A total of 2.15 million shares were traded on the day, compared to an average of 7.24M shares.
Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, MRSN has seen 3 BUY and 1 SELL insider trades, representing the acquisition of 16,546 and the disposition of 1,908 shares. Over the last 12 months, there were 31 BUYs and 10 SELLs from insiders. Insiders purchased 306,513 shares during that period but sold 47,113.
In the most recent transaction, MISRA TUSHAR sold 1,908 shares of MRSN for 1.18 per share on Aug 17. After the transaction, the SVP, Chief Manuf. Officer now owns 11,507 company shares. In a previous transaction on Apr 27, Carvajal Alejandra sold 3,944 shares at 3.89 per share. MRSN shares that SVP, Chief Legal Officer owns now total 20,326.
Among the insiders who sold shares, Protopapas Anna disposed of 17,346 shares on Jan 17 at a per-share price of $5.74. This resulted in the President & CEO holding 48,733 shares of MRSN after the transaction. In another insider transaction, Lowinger Timothy B sold 6,233 shares at $5.74 per share on Jan 17. Company shares held by the SVP, Chief Sci.&Tech. Off. now total 180,363.
While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for MRSN in the last 3 months, the mean price target is $2.00 with high estimates of $4.00 and low estimates of $1.00. In terms of 52-week highs and lows, MRSN has a high of $9.62 and a low of $0.80.
As of this writing, MRSN has an earnings estimate of -$0.36 per share for the current quarter. EPS was calculated based on a consensus of 9 estimates, with a high estimate of -$0.24 per share and a lower estimate of -$0.6. The company reported an EPS of -$0.52 in the last quarter, which was -18.20% lower than expectations of -$0.44.
Balance Sheet Annually/Quarterly
An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information. MRSN’s latest balance sheet shows that the firm has $177.95M in Cash & Short Term Investments as of fiscal 2021. There were $38.18M in debt and $47.52M in liabilities at the time. Its Book Value Per Share was $0.78, while its Total Shareholder’s Equity was $121.74M.
There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for MRSN is Buy with a score of 3.22.